|Mr. Kyle Makofka||Chief Exec. Officer||105.76k||N/A||N/A|
|Dr. Alan J. Jacobs M.D., Ph.D.||Pres & Chief Medical Officer||N/A||N/A||N/A|
|Ms. Kristin Gulka CPA, CA||Chief Financial Officer||N/A||N/A||N/A|
|Ms. Eilat Bain||Director of Operations||N/A||N/A||N/A|
Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia. It is also developing various types of cells products, such as synergetic cell precursors, myocardial cell precursors, and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
Hemostemix Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.